[
    [
        {
            "time": "2023-10-10",
            "original_text": "An Intrinsic Calculation For Novo Nordisk A/S (CPH:NOVO B) Suggests It's 25% Undervalued",
            "features": {
                "keywords": [
                    "Intrinsic Calculation",
                    "Novo Nordisk",
                    "Undervalued"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "An Intrinsic Calculation For Novo Nordisk A/S (CPH:NOVO B) Suggests It's 25% Undervalued",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "2023-10-10",
            "original_text": "Insulin maker Novo Nordisk walks moral tightrope",
            "features": {
                "keywords": [
                    "Insulin",
                    "Novo Nordisk",
                    "moral tightrope"
                ],
                "sentiment_score": 0.4,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Insulin maker Novo Nordisk walks moral tightrope",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2023-10-10",
            "original_text": "Novo Nordisk walks tightrope on moral mission",
            "features": {
                "keywords": [
                    "Novo Nordisk",
                    "tightrope",
                    "moral mission"
                ],
                "sentiment_score": 0.5,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Novo Nordisk walks tightrope on moral mission",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 5
            }
        }
    ]
]